睿知中国疾病研究地图
候选清单0

即将招募肝细胞癌不分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Multimodal Thermal Therapy With Targeted and Immunotherapy for Untreated Unresectable HCC

ClinicalTrials.gov 上登记的一项肝细胞癌开放试验。牵头方不是本站收录的医院;本站收录的 4 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 4

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面
  2. 研究中心南昌大学第二附属医院Second Affiliated Hospital of Nanchang University南昌医院页面
  3. 研究中心浙江大学医学院附属第二医院Second Affiliated Hospital, Zhejiang University杭州医院页面
  4. 研究中心温州医科大学附属台州医院Taizhou Hospital, Wenzhou Medical University台州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07596134,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Diagnosed with unresectable HCC by imaging or histology, BCLC stage B or C;

    入选标准第 2 条

  3. Child-Pugh score ≤7;

    入选标准第 5 条

  4. Presence of an image-evaluable lesion intended for ablation without prior local ablation therapy, with the maximum diameter of the target tumor ≤5 cm;

    入选标准第 4 条

    Prior local therapy with the last treatment administered less than 4 weeks before enrollment;

    排除标准第 6 条

    Pregnant or breastfeeding women, or women of childbearing potential planning pregnancy during the study or within 3 months after treatment completion;

    排除标准第 15 条

  5. ECOG-PS score of 0-1.

    入选标准第 6 条

  6. Renal dysfunction with serum creatinine >176.8 μmol/L or creatinine clearance <30 mL/min;

    排除标准第 9 条

    Uncorrectable coagulation abnormalities: platelets <50×10⁹/L, prothrombin time >18 seconds, prothrombin activity <40%, and uncorrectable;

    排除标准第 10 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶;试验排除的其他疾病;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07596134,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. • Age 18-80, regardless of gender;
  2. Diagnosed with unresectable HCC by imaging or histology, BCLC stage B or C;
  3. No prior systemic immunotherapy, chemotherapy, targeted therapy, or other systemic drug treatments for HCC;
  4. Presence of an image-evaluable lesion intended for ablation without prior local ablation therapy, with the maximum diameter of the target tumor ≤5 cm;
  5. Child-Pugh score ≤7;
  6. ECOG-PS score of 0-1.

排除标准:Exclusion Criteria:

  1. • Invasion of the main portal vein;
  2. Diffuse hepatocellular carcinoma;
  3. The hepatic lesion occupies more than 50% of the liver volume.
  4. Patients with a history or current diagnosis of brain metastases whose symptoms are not fully controlled (i.e., persistent or worsening symptoms, or requiring adjustments to symptomatic treatment to maintain symptom relief);
  5. Extensive distant metastasis confirmed by imaging (e.g., chest/abdominal CT/MRI, whole-body bone scan, PET-CT, etc.), including but not limited to diffuse lung metastasis, multiple bone metastases, extensive abdominal/peritoneal metastasis, or other multi-organ metastases, where the investigator assesses that the extent of metastasis may compromise the safe administration of study treatment or affect efficacy and safety evaluations;
  6. Prior local therapy with the last treatment administered less than 4 weeks before enrollment;
  7. Involvement of major blood vessels such as the hepatic vein or inferior vena cava;
  8. Uncontrolled active infection;
  9. Renal dysfunction with serum creatinine >176.8 μmol/L or creatinine clearance <30 mL/min;
  10. Uncorrectable coagulation abnormalities: platelets <50×10⁹/L, prothrombin time >18 seconds, prothrombin activity <40%, and uncorrectable;
  11. History of esophageal or gastric variceal bleeding without effective treatment via endoscopy, intervention, or surgery;
  12. Patients with active psychiatric disorders;
  13. Patients receiving or requiring systemic glucocorticoids (e.g., prednisone, dexamethasone) at a dose ≥10 mg/day (prednisone equivalent) or other immunosuppressive drugs (e.g., cyclosporine, tacrolimus, methotrexate) within 14 days prior to enrollment; topical, inhaled, or ophthalmic glucocorticoid use that does not affect systemic immune function may be allowed at the investigator's discretion;
  14. History or current diagnosis of malignancies other than the target tumor in this study (excluding cured low-grade malignancies such as basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ). For low-grade malignancies, eligibility will be determined by the investigator;
  15. Pregnant or breastfeeding women, or women of childbearing potential planning pregnancy during the study or within 3 months after treatment completion;
  16. Expected survival <3 months;
  17. Patients deemed unsuitable for participation by the investigator.

引自 ClinicalTrials.gov, NCT07596134, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07596134,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07596134